Bispecific vs Monospecific ADCs

Bispecific ADCs targeting two tumor associated antigens (TAAs) are a brand-new form of ADC concept which is building on the advantages and success of existing ADCs. Dual targets increase the specificity of tumor targeting and reduce the toxicity to normal tissues.

Bispecific ADCs can produce better internalization and deliver better tumor killing, overcome the problem of drug resistance caused by decreased single-target expression and deliver greater killing of tumors that express low levels of individual target antigens.

To date, 14 ADCs have been approved by the FDA, and there are a few bi approved ADCs, a few bispecifics in preclinic.

Radiance’s mission is to deliver the the first approved bispecific ADC.